Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03815942
Recruitment Status : Recruiting
First Posted : January 24, 2019
Last Update Posted : February 8, 2019
Sponsor:
Collaborator:
Vaccitech Limited
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer. A vaccine that could alert the immune system to the presence of cancer cells in the body may enable the immune system to target and kill those cells effectively. This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells. The vaccine is made up of two recombinant viruses ("ChAdOx1"- chimpanzee adenovirus Ox1 and "MVA" - modified vaccinia Ankara) that have been designed to produce the 5T4 protein and have been modified so that they are weakened and cannot reproduce themselves within the body like normal viruses. Once injected into the body, these viruses make the 5T4 protein and help the body's immune system to learn to target this protein and destroy cancer cells.

This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody. This is a molecule that releases the brakes on the immune system and helps the immune system to kill cancer cells more efficiently. Nivolumab as a monotherapy was approved for treatment of several tumour types but not for the prostate cancer.

This study will evaluate the safety and efficacy of ChAdOx1-MVA 5T4 vaccine in combination with nivolumab in low and intermediate risk prostate cancer patients who have elected to have their prostate removed and in patients with advanced metastatic prostate cancer.


Condition or disease Intervention/treatment Phase
Intermediate Risk Prostate Cancer Castration-resistant Prostate Cancer Biological: ChAdOx1-MVA 5T4 vaccine Drug: Nivolumab Infusion [Opdivo] Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Open Label Non-randomised Safety and Efficacy Study of the Viral Vectored ChAd-MVA 5T4 Vaccine in Combination With PD-1 Checkpoint Blockade in Low- or Intermediate-risk Localized or Locally Advanced Prostate Cancer and Advanced Metastatic Prostate Cancer
Actual Study Start Date : December 10, 2018
Estimated Primary Completion Date : December 10, 2020
Estimated Study Completion Date : May 10, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Intermediate risk prostate cancer
ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
Biological: ChAdOx1-MVA 5T4 vaccine
ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10^8 plaque forming units

Drug: Nivolumab Infusion [Opdivo]
Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
Other Name: anti-PD-1 monoclonal antibody

Experimental: Advanced metastatic prostate cancer
ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
Biological: ChAdOx1-MVA 5T4 vaccine
ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10^8 plaque forming units

Drug: Nivolumab Infusion [Opdivo]
Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
Other Name: anti-PD-1 monoclonal antibody




Primary Outcome Measures :
  1. Safety - incidence of treatment-related adverse events. [ Time Frame: From baseline to 12 months ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  2. Efficacy - measure composite response rate defined as one of the following: 1) change in circulating tumour DNA, 2) change in serum PSA [ Time Frame: From baseline to 12 months ]
    Number of participants with 50% or more change in ctDNA or PSA concentration in the blood from baseline to 12 months post treatment


Secondary Outcome Measures :
  1. Evaluate immune responses to the vaccine antigen in the periphery [ Time Frame: From baseline to 12 months ]
    Number of participants with peripheral 5T4-specific T cell responses secondary to treatment

  2. Evaluate immune cell subsets in the prostate secondary to treatment (for surgical cohort) [ Time Frame: From baseline to radical prostatectomy, an expected average of 6 weeks ]
    Number of participants with intraprostatic infiltration of CD3+CD8+ T cells secondary to treatment

  3. Evaluate progression-free survival following study treatment (for advanced metastatic cancer cohort) [ Time Frame: 6-12 months ]
    Number of participants experiencing progression-free survival at 6 and 12 months post treatment

  4. Evaluate overall survival following study treatment (for advanced metastatic cancer cohort) [ Time Frame: 6-12 months ]
    Number of participants experiencing overall survival at 6 and 12 months post treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

For all participants:

  • Histologically confirmed adenocarcinoma of the prostate cancer
  • Any antineoplastic therapy must have been completed a minimum of 28 days prior to enrolment
  • Systemic antimicrobial therapy must have been completed a minimum of 7 days prior to enrolment
  • An archival specimen of tumour tissue should be available
  • Baseline laboratory parameters must meet the following criteria:

Haemoglobin ≥ 80 g/L, White cell count ≥ 2.0 x10^9/L, Neutrophils ≥ 1.5 x10^9/L, Lymphocytes ≥ 0.5 x10^9/L, Platelets ≥ 100 x10^9/L, Creatinine Clearance ≥ 40 ml/min by Cockcroft Gault formulation, Total Bilirubin ≤ 1.5 ULN, Alanine Aminotransferase ≤ 1.5 ULN, Amylase ≤ 1.5 ULN

For surgical cohort:

  • Clinically localised or locally advanced disease deemed operable by the treating consultant urological surgeon i.e.: Gleason score ≤ 7, local tumour stage ≤T3c and deemed operable, no evidence of metastases (Nx/N0 and Mx/M0), no evidence of high grade Gleason 5 disease, PSA ≤ 20 ng/ml
  • Scheduled for and considered fit for radical prostatectomy

For advanced metastatic cohort:

  • Evidence of at least one distant metastasis based on MRI, CT, PET or bone scintigraphy
  • Established on and suitable to continue with androgen deprivation therapy (ADT) using any luteinizing hormone releasing hormone (LHRH) agonist
  • On treatment with anti-androgen therapy using either abiraterone (Zytiga®) or enzalutamide (Xtandi®) and demonstrating evidence of disease progression at the time of enrolment
  • Suitable to continue therapy with either abiraterone or enzalutamide at the time of enrolment at discretion of their managing clinician
  • Patients who have received chemotherapy following progression on androgen-targeting therapies are eligible
  • Satisfactory functional status defined as ECOG Performance Status ≤ 1

Exclusion Criteria:

For all participants:

  • Any prior diagnosis or clinical suspicion of autoimmune disease
  • History of allergic disease or reaction likely to be exacerbated by any component of the vaccine, e.g. egg products
  • Other prior malignancy with an estimated ≥ 30% chance of relapse within 2 years
  • Participation in another research study involving an investigational product or investigational surgical procedure in the 30 days preceding enrolment, or planned use during the study period
  • Any prior exposure to checkpoint inhibitor drugs including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monoclonal antibodies or any prior treatment with investigational vaccines
  • Administration of immunoglobulins and/or any blood products within the one month preceding the planned administration of the study drugs
  • Seropositive for hepatitis B surface antigen (HBsAg)
  • Seropositive for hepatitis C virus (antibodies to HCV)
  • Any confirmed or suspected immunocompromised state
  • Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema
  • History of anaphylaxis in relation to vaccination or any clinically significant allergic disease likely to be exacerbated by any component of the vaccine or checkpoint inhibitor preparations

For advanced metastatic cohort:

  • The treating oncologist estimates a subject's life expectancy to be ≤ 6 months
  • Any active, previously treated, or suspected intracranial or leptomeningeal metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03815942


Contacts
Layout table for location contacts
Contact: Mark Tuthill +441865 227042 mark.tuthill@ouh.nhs.uk
Contact: Irina Redchenko +441865 617623 irina.redchenko@ndm.ox.ac.uk

Locations
Layout table for location information
United Kingdom
Cancer Institute, University College London Not yet recruiting
London, United Kingdom, WC1E 6DD
Principal Investigator: Mark Linch         
Department of Oncology, The Christie NHS Foundation Trust Recruiting
Manchester, United Kingdom, M20 4BX
Principal Investigator: Silke Gillessen         
Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Recruiting
Oxford, United Kingdom, OX3 7LE
Principal Investigator: Andrew Protheroe         
Sponsors and Collaborators
University of Oxford
Vaccitech Limited
Investigators
Layout table for investigator information
Study Chair: Adrian VS Hill University of Oxford

Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03815942     History of Changes
Other Study ID Numbers: ADVANCE
First Posted: January 24, 2019    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Nivolumab
Vaccines
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents